Literature DB >> 3734355

Importance of laboratory parameters in the evaluation of Crohn's disease activity.

C Brignola, G A Lanfranchi, M Campieri, G Bazzocchi, M Devoto, P Boni, P Farruggia, S Veggetti, A Tragnone.   

Abstract

Some laboratory investigations are abnormal during the course of Crohn's disease (CD). We investigated the trend of some of these laboratory tests in a group of patients with CD to study the relationships between an activity index made up of such laboratory parameters only (LCDAI) and the usual Crohn's disease activity index (CDAI). One hundred thirty-one examinations of 63 patients were evaluated. At each investigation, besides calculation of the CDAI, 10 laboratory investigations were carried out. Three gastroenterologists independently gave an overall evaluation of the laboratory activity for each of the 131 examinations on the basis of the results of the blood tests alone. The sum of the evaluations was used as an independent variable on which a laboratory index was developed by multiple regression analysis. C reactive protein, red cell sedimentation rate, acid alpha 1-glycoprotein, alpha 1-antitrypsin, and white blood cells had an important share in the development of this laboratory index. The evaluation of the relationships existing between LCDAI and CDAI showed that in patients with moderate to severe clinical disease activity, LCDAI was constantly altered. The same happened in 55% of cases in clinical remission, which suggests an inflammatory activity that is not clinically evident. These results point to the advisability of supplementing a predominantly clinical index, such as CDAI, with a laboratory index such as LCDAI in the evaluation of CD.

Entities:  

Mesh:

Year:  1986        PMID: 3734355     DOI: 10.1097/00004836-198606000-00008

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  13 in total

1.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  T Kaiser; J Langhorst; H Wittkowski; K Becker; A W Friedrich; A Rueffer; G J Dobos; J Roth; D Foell
Journal:  Gut       Date:  2007-08-03       Impact factor: 23.059

2.  European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis.

Authors:  E F Stange; S P L Travis; S Vermeire; C Beglinger; L Kupcinkas; K Geboes; A Barakauskiene; V Villanacci; A Von Herbay; B F Warren; C Gasche; H Tilg; Stefan W Schreiber; J Schölmerich; W Reinisch
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

3.  Intestinal permeability in gastrointestinal disorders. Use of oral [99mTc]DTPA.

Authors:  R H Resnick; H Royal; W Marshall; R Barron; T Werth
Journal:  Dig Dis Sci       Date:  1990-02       Impact factor: 3.199

4.  Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease.

Authors:  C Brignola; P Iannone; S Pasquali; M Campieri; P Gionchetti; A Belluzzi; O Basso; M Miglioli; L Barbara
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

5.  Predicting relapses of Crohn's disease. Clouds in the crystal ball.

Authors:  D B Sachar
Journal:  Dig Dis Sci       Date:  1987-02       Impact factor: 3.199

6.  Faecal diversion for Crohn's colitis: a model to study the role of the faecal stream in the inflammatory process.

Authors:  M C Winslet; A Allan; V Poxon; D Youngs; M R Keighley
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

7.  Serum immunomodulatory factors in gastrointestinal diseases. A 30-50-kD serum fraction in Crohn's disease capable of modulating lymphocyte activation.

Authors:  L Biancone; M Boirivant; S Fais; G L Ricci; R Paganelli; F Pallone
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

8.  Relationship between intestinal permeability to [51Cr]EDTA and inflammatory activity in asymptomatic patients with Crohn's disease.

Authors:  L Pironi; M Miglioli; E Ruggeri; M Levorato; M A Dallasta; C Corbelli; M G Nibali; L Barbara
Journal:  Dig Dis Sci       Date:  1990-05       Impact factor: 3.199

9.  Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease.

Authors:  D Foell; T Kucharzik; M Kraft; T Vogl; C Sorg; W Domschke; J Roth
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 10.  How to predict clinical relapse in inflammatory bowel disease patients.

Authors:  Elisa Liverani; Eleonora Scaioli; Richard John Digby; Matteo Bellanova; Andrea Belluzzi
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.